A video goggle-based technology may help increase visual acuity (VA) in children with amblyopia.
A video goggle-based technology called Reviview may help increase visual acuity (VA) in children with amblyopia. The technology is based on the principle that any video content can be transformed into a useful treatment tool for amblyopia.
According to co-inventors Ilan Vadai and Yuval Avni, Reviview incorporates brain stimulation technology designed to improve vision via a set of dedicated video goggles. To improve his or her visual acuity, a child wears the goggles to watch 30 to 60 minutes of their favourite animated television shows per day.
Vadai and Avni both have backgrounds in medical device design; Vadi also has a background in video production.
According to Vadai and Avni, in a study of 16 children aged 4 to 8 years who were provided with prototypes of the device, watching 30 to 60 minutes of their favourite animated television shows led to improvements in VA in 88% of the participants. Improvements after 4 weeks ranged from 1 LogMAR line up to 5 LogMAR lines. The average improvement was 2 lines (±1.7 lines) after 4 weeks and 2.6 lines (±1.5 lines) after 8 weeks.
"Adherence is a major problem with amblyopia treatment routines. With our approach, the fun of the treatment and the fast results contribute to the high level of commitment we see among kids and parents to our unique and patented treatment process," Vadai said.
He added that the goggles could be ready for marketing in about 12 months, and the company is looking for funding to finish the product design and conduct further studies.
For more information go to www.visiortech.com.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.